Semaglutide, the active pharmaceutical ingredient in Ozempic®, Wegovy™,
and Rybelsus®, belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the GLP-1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP-1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness to help patients with weight management.

It slows the rate food moves through your digestive system, known as gastric emptying, which tells your brain there’s food in your stomach, and reduces your appetite and food cravings.  Smaller quantities of food keep you satisfied longer, so you’re not hungry as often as usual. You consume fewer calories than you use for your daily activities, resulting in easy and effective weight loss.

Semaglutide is a painless weekly shot that you administer from the comfort of your own home. Your medication delivery will contain specific directions on how to administer the medication to yourself subcutaneously (under the skin). If you have any questions, please reach out to your Healthcare Team to ensure you’re dispensing the medication correctly.

Semaglutide is only right for some people. According to the Obesity Medicine Association adults with obesity (BMI 30 or more) or overweight (BMI 27-29) with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), are eligible to receive it if there are no contraindications.

Your Healthcare Provider will personalize the dosage based on your current health status, health history, and other factors, which will be reassessed regularly. Upon approval by your Healthcare provider, you will begin using Semaglutide with the proper dose to minimize side effects. Thereafter, the doses may increase and once you reach your weight loss goal, your provider will prescribe a low-dose maintenance plan.

Tirzepatide, the active pharmaceutical ingredient in Mounjaro® (tirzepatide) and Zepbound® (tirzepatide), belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. Tirzepatide is a prescription medicine that may help adults with obesity or excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off, and improves blood sugar (glucose) in adults with type 2 diabetes mellitus.

“Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes,” said John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research. “In light of increasing rates of both obesity and overweight in the United States, today’s [tirzepatide] approval addresses an unmet medical need.”

Approximately 70% of American adults have obesity or overweight, and many of those overweight have a weight-related condition. Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adults with obesity or overweight.

It activates receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake to help patients with weight management. It reduces your appetite and food cravings, so you consume fewer calories than you use for your daily activities, resulting in easy and effective weight loss.

Tirzepatide is a painless weekly shot that you administer from the comfort of your own home. Your medication delivery will contain specific directions on how to administer the medication to yourself subcutaneously (under the skin). If you have any questions, please reach out to your Healthcare Team to ensure you’re dispensing the medication correctly.

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter (kg/ m2) or greater) or overweight (body mass index of 27 kg/m2 or greater) with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity. Tirzepatide is only right for some people.

Your Healthcare Provider will personalize the dosage based on your current health status, health history, and other factors, which will be reassessed regularly. Upon approval by your Healthcare provider, you will begin using Tirzepatide with the proper dose to minimize side effects. Thereafter, the doses may increase and once you reach your weight loss goal, your provider will prescribe a low-dose maintenance plan.